JP2021527062A - ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 - Google Patents

ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 Download PDF

Info

Publication number
JP2021527062A
JP2021527062A JP2020567973A JP2020567973A JP2021527062A JP 2021527062 A JP2021527062 A JP 2021527062A JP 2020567973 A JP2020567973 A JP 2020567973A JP 2020567973 A JP2020567973 A JP 2020567973A JP 2021527062 A JP2021527062 A JP 2021527062A
Authority
JP
Japan
Prior art keywords
treatment
level
complement factor
administering
abacopan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020567973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527062A5 (OSRAM
Inventor
トン チュン
ベッカー ペトラス
ヒルソン ジャン
Original Assignee
ケモセントリックス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケモセントリックス，インコーポレイティド filed Critical ケモセントリックス，インコーポレイティド
Publication of JP2021527062A publication Critical patent/JP2021527062A/ja
Publication of JP2021527062A5 publication Critical patent/JP2021527062A5/ja
Priority to JP2024088364A priority Critical patent/JP2024114706A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020567973A 2018-06-07 2019-06-06 ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 Pending JP2021527062A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024088364A JP2024114706A (ja) 2018-06-07 2024-05-30 ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682013P 2018-06-07 2018-06-07
US62/682,013 2018-06-07
PCT/US2019/035758 WO2019236820A1 (en) 2018-06-07 2019-06-06 Dosing and effect of c5a antagonist with anca-associated vasculitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024088364A Division JP2024114706A (ja) 2018-06-07 2024-05-30 ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果

Publications (2)

Publication Number Publication Date
JP2021527062A true JP2021527062A (ja) 2021-10-11
JP2021527062A5 JP2021527062A5 (OSRAM) 2022-06-13

Family

ID=68764799

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020567973A Pending JP2021527062A (ja) 2018-06-07 2019-06-06 ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果
JP2024088364A Pending JP2024114706A (ja) 2018-06-07 2024-05-30 ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024088364A Pending JP2024114706A (ja) 2018-06-07 2024-05-30 ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果

Country Status (15)

Country Link
US (2) US11191756B2 (OSRAM)
EP (1) EP3801519A4 (OSRAM)
JP (2) JP2021527062A (OSRAM)
KR (2) KR20210018906A (OSRAM)
CN (1) CN112423752A (OSRAM)
AU (1) AU2019282327B2 (OSRAM)
BR (1) BR112020024842A2 (OSRAM)
CA (1) CA3102403A1 (OSRAM)
CL (1) CL2020003171A1 (OSRAM)
IL (1) IL279188B2 (OSRAM)
MA (1) MA52808A (OSRAM)
MX (1) MX2020013166A (OSRAM)
SG (1) SG11202011961YA (OSRAM)
WO (1) WO2019236820A1 (OSRAM)
ZA (1) ZA202007615B (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3102403A1 (en) 2018-06-07 2019-12-12 Chemocentryx, Inc. Dosing and effect of c5a antagonist with anca-associated vasculitis
EP4487915A3 (en) 2018-11-30 2025-03-19 ChemoCentryx, Inc. Capsule formulations
MX2022005406A (es) 2019-11-08 2022-05-24 Chemocentryx Inc Forma amorfa de un receptor de componente c5a de complemento.
CN118908883A (zh) * 2019-11-08 2024-11-08 凯莫森特里克斯股份有限公司 补体成分c5a受体的盐形式

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515073A (ja) * 2008-02-20 2011-05-19 ジーツー インフラメイション プロプライエタリー リミテッド ヒト化抗Ｃ５ａＲ抗体
JP2012513402A (ja) * 2008-12-22 2012-06-14 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
WO2008079371A1 (en) * 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
HRP20171176T1 (hr) 2010-06-24 2017-10-06 Chemocentryx, Inc. C5ar antagonisti
EP3682879B1 (en) 2014-09-29 2022-08-03 ChemoCentryx, Inc. Processes and intermediates in the preparation of c5ar antagonists
EP3283889B1 (en) 2015-04-17 2020-02-26 Euroimmun Medizinische Labordiagnostika AG Method and assay for diagnosing rapidly progressive glomerulonephritis in a subject
WO2017176620A2 (en) 2016-04-04 2017-10-12 Chemocentryx, Inc. SOLUBLE C5aR ANTAGONISTS
US20190134020A1 (en) * 2017-10-31 2019-05-09 Chemocentryx, Inc. C5aR INHIBITOR REDUCTION OF URINARY sCD163
CA3102403A1 (en) 2018-06-07 2019-12-12 Chemocentryx, Inc. Dosing and effect of c5a antagonist with anca-associated vasculitis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515073A (ja) * 2008-02-20 2011-05-19 ジーツー インフラメイション プロプライエタリー リミテッド ヒト化抗Ｃ５ａＲ抗体
JP2012513402A (ja) * 2008-12-22 2012-06-14 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANN THORAC SURG, vol. 83, JPN6023020500, 2007, pages 146 - 152, ISSN: 0005064189 *
BRITISH JOURNAL OF PHARMACOLOGY, vol. 168, JPN6023020499, 2013, pages 488 - 501, ISSN: 0005064188 *
INFLAMMATION AND REGENERATION, vol. 36, JPN6023020498, 2016, pages 1 - 5, ISSN: 0005248425 *
J AM SOC NEPHROL, vol. 28, JPN6023020496, 2017, pages 2756 - 2767, ISSN: 0005248423 *
J CLIN INVEST, vol. 124(1), JPN6023020495, 2014, pages 145 - 155, ISSN: 0005064190 *
RHEUMATOL INT, vol. 37, JPN6023020497, 2017, pages 1779 - 1788, ISSN: 0005248424 *

Also Published As

Publication number Publication date
CN112423752A (zh) 2021-02-26
JP2024114706A (ja) 2024-08-23
EP3801519A1 (en) 2021-04-14
BR112020024842A2 (pt) 2021-03-02
MX2020013166A (es) 2021-03-29
SG11202011961YA (en) 2020-12-30
US12350263B2 (en) 2025-07-08
US11191756B2 (en) 2021-12-07
KR20210018906A (ko) 2021-02-18
WO2019236820A1 (en) 2019-12-12
US20190374524A1 (en) 2019-12-12
EP3801519A4 (en) 2022-03-30
AU2019282327B2 (en) 2025-04-24
CL2020003171A1 (es) 2021-06-04
AU2019282327A1 (en) 2021-01-07
MA52808A (fr) 2021-04-14
IL279188B1 (en) 2025-12-01
IL279188B2 (en) 2026-04-01
KR20260027358A (ko) 2026-02-27
ZA202007615B (en) 2024-05-30
IL279188A (en) 2021-01-31
US20220296576A1 (en) 2022-09-22
CA3102403A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
JP2024114706A (ja) ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果
TWI764996B (zh) 含西里帕格之醫藥組成物
JP6203734B2 (ja) 変形性関節疾患の治療
EP2211896A2 (en) Compositions for the treatment of gastrointestinal inflammation
US20250367229A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
BR112019020451A2 (pt) composições e métodos para se direcionar e matar células-tronco positivas de câncer ?lfa-v beta-3 positiva (cscs) e tratamento de cânceres resistentes ao medicamento
MXPA04011794A (es) Composiciones para uso terapeutico que comprenden una vitamina, una sal de metal e insulina o una hormona de crecimiento.
Kumar et al. Gouty arthritis treatment: advancements in topical lipid-based nanocarrier delivery systems
CN111671725B (zh) 用于保护缺血心肌的注射剂及其制备方法
RU2322238C2 (ru) Лечение ревматоидного артрита
WO2022003443A1 (ko) 양이온성 리포좀을 포함하는 사포닌의 용혈 억제용 조성물
EP2808025B1 (en) Pharmaceutical composition and quasi-drug cosmetic using same
JP6051315B2 (ja) 乾癬を処置するためのピドチモドの使用
RU2835509C2 (ru) Дозирование и эффект c5a антагониста при anca-ассоциированном васкулите
WO2018226939A1 (en) Compositions and methods of treating and/or preventing cancer
US20250387363A1 (en) Liquid epinephrine prodrug formulations and liquid epinephrine formulations
US20250387371A1 (en) Compositions and formulation methods for sustained local release of antifibrotics
WO2025018279A1 (ja) ヒト移植片対宿主病の治療薬およびその組合せ物
TWI620566B (zh) 三萜混合物用以治療多發性硬化的用途
AU2024359177A1 (en) Methods and compositions for treating behçet's disease
WO2025080629A1 (en) Methods and compositions for treating behçet's disease
HK40129829A (zh) 尿毒症瘙痒的治疗
WO2020116570A1 (ja) 皮膚外用剤
HK1204556B (en) Pharmaceutical composition and quasi-drug cosmetic using same
EP2590640A1 (en) Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20210125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220603

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240530

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240712

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20241101